☆ 4.7 Review

Improving cancer immunotherapy by rationally combining oncolytic virus with modulators targeting key signaling pathways

MOLECULAR CANCER (2022)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Oncology

Targeting Fc Receptor-Mediated Effects and the Don't Eat Me Signal with an Oncolytic Virus Expressing an Anti-CD47 Antibody to Treat Metastatic Ovarian Cancer

Lei Tian et al.

Summary: The use of anti-CD47 antibodies as cancer therapeutics has been proven effective but is associated with severe toxicity. By engineering an oncolytic herpesvirus to express anti-CD47 antibodies, the therapeutic efficacy for ovarian cancer can be improved while reducing toxicities.

CLINICAL CANCER RESEARCH (2022)

添加到收藏夹

Article Oncology

First-in-Human Phase I/IB Dose-Finding Study of Adagrasib (MRTX849) in Patients With Advanced KRASG12C Solid Tumors (KRYSTAL-1)

Sai-Hong Ignatius Ou et al.

Summary: This study reported the results of a clinical trial using adagrasib to treat non-small-cell lung cancer, colorectal cancer, and other solid tumors with the KRAS(G12C) mutation. The recommended phase II dose was identified as 600 mg twice a day, and it demonstrated good tolerability and antitumor activity.

JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

Review Biotechnology & Applied Microbiology

Histone modifiers at the crossroads of oncolytic and oncogenic viruses

Sara A. Murphy et al.

Summary: Cancer is a disease caused by the loss of regulatory processes controlling the cell cycle, resulting in increased cell proliferation. Besides gene mutations and environmental factors, cancer-causing viruses can induce changes leading to malignant transformation. Epigenetic modifiers are effective therapeutic targets, and several drugs targeting epigenetic modifications have been approved for cancer treatment. In addition to small molecule drugs, biological therapies such as antibodies and viral therapies are also used in cancer treatment. The interaction between epigenetic drugs and oncogenic and oncolytic viruses is an important area of investigation.

MOLECULAR THERAPY (2022)

添加到收藏夹

Review Oncology

Radiotherapy as a tool to elicit clinically actionable signalling pathways in cancer

Giulia Petroni et al.

Summary: Targeted anticancer agents have been successful in inhibiting specific molecular alterations in cancer cells, while radiotherapy activates cytotoxic pathways and protective mechanisms that can enhance the efficacy of these agents. By promoting non-oncogene dependence on targetable signaling pathways, radiotherapy has the potential to benefit a greater number of patients who may not respond to targeted therapies alone.

NATURE REVIEWS CLINICAL ONCOLOGY (2022)

添加到收藏夹

Review Oncology

Hallmarks of Cancer: New Dimensions

Douglas Hanahan

Summary: The concept of the hallmarks of cancer is a tool for simplifying the complexity of cancer phenotypes and genotypes into basic principles. This article proposes phenotypic plasticity and disrupted differentiation as distinct hallmark capabilities, and discusses nonmutational epigenetic reprogramming and polymorphic microbiomes as enabling characteristics. Additionally, the importance of senescent cells in the tumor microenvironment is highlighted. The integrative concept of the hallmarks of cancer helps in understanding the mechanisms of cancer development and applying that knowledge to cancer medicine.

CANCER DISCOVERY (2022)

添加到收藏夹

Article Medicine, Research & Experimental

Inhibition of MEK-ERK pathway enhances oncolytic vaccinia virus replication in doxorubicin-resistant ovarian cancer

Seoyul Lee et al.

Molecular Therapy-Oncolytics (2022)

添加到收藏夹

Review Oncology

Remodeling the tumor microenvironment by oncolytic viruses: beyond oncolysis of tumor cells for cancer treatment

Lihong Wang et al.

Summary: Tumor cells manipulate the local environment to create a tumor microenvironment (TME) that promotes tumor survival and metastasis. Oncolytic viruses (OVs) are a promising therapeutic approach that can modify the TME to activate antitumor immune cells and overcome tumor therapeutic resistance and recurrence. This review discusses the tropism of OVs towards tumor cells and their interaction with immune cells, tumor stroma, vasculature, and the metabolic environment.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)

添加到收藏夹

Article Oncology

CORE1: Phase 2, single-arm study of CG0070 combined with pembrolizumab in patients with nonmuscle-invasive bladder cancer (NMIBC) unresponsive to bacillus Calmette-Guerin (BCG).

Roger Li et al.

JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

Article Medicine, General & Internal

Adagrasib in Non-Small-Cell Lung Cancer Harboring a KRASG12C Mutation

Pasi A. Jaenne et al.

Summary: Adagrasib demonstrated clinical efficacy without new safety signals in previously treated KRAS(G12C)-mutated NSCLC patients.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

添加到收藏夹

Article Medicine, General & Internal

Oncolytic DNX-2401 Virus for Pediatric Diffuse Intrinsic Pontine Glioma

Jaime Gallego Perez-Larraya et al.

Summary: This study investigated the use of oncolytic virus DNX-2401 in pediatric patients with diffuse intrinsic pontine glioma (DIPG). The results showed that treatment with DNX-2401 led to changes in T-cell activity and reduction or stabilization of tumor size in some patients, but also caused adverse events.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

添加到收藏夹

Article Biochemistry & Molecular Biology

Ferroptosis Inducer Improves the Efficacy of Oncolytic Virus-Mediated Cancer Immunotherapy

Weilin Liu et al.

Summary: The study found that the combination of the ferroptosis activator Erastin with the oncolytic vaccinia virus could effectively inhibit tumor growth, prolong host survival, and enhance antitumoral immunity in hepatocellular carcinoma and colon cancer models.

BIOMEDICINES (2022)

添加到收藏夹

Article Oncology

Teserpaturev/G47Δ: First Approval

James E. Frampton

Summary: This article summarizes the development milestones of Teserpaturev/G47 Delta leading to its first approval for the treatment of malignant glioma.

BIODRUGS (2022)

添加到收藏夹

Review Biotechnology & Applied Microbiology

The expanding role for small molecules in immuno-oncology

Rienk Offringa et al.

Summary: This review provides an update on the application of small-molecule drugs in immuno-oncology, focusing on their use in stimulating the antitumour immune response and targeting T cell checkpoints. The review highlights the combination of antibody-based immune checkpoint inhibitors with small molecules, as well as the recent milestones and hurdles in this field of drug development.

NATURE REVIEWS DRUG DISCOVERY (2022)

添加到收藏夹

Review Immunology

Current clinical landscape of oncolytic viruses as novel cancer immunotherapeutic and recent preclinical advancements

Chae-Ok Yun et al.

Summary: Oncolytic viruses have gained attention in the pharmaceutical industry for their ability to induce and boost antitumor immunity through multiple mechanisms. These unique characteristics make oncolytic viruses promising in the field of immune-oncology.

FRONTIERS IN IMMUNOLOGY (2022)

添加到收藏夹

Article Biochemistry & Molecular Biology

Identification of the receptor of oncolytic virus M1 as a therapeutic predictor for multiple solid tumors

Deli Song et al.

Summary: Oncolytic virus therapy has shown promising potential in tumor treatment, but not all patients benefit from it. In this study, MXRA8 was identified as a factor positively correlated with oncolysis induced by OVM, and it was found to promote the oncolytic efficacy of OVM. Furthermore, MXRA8 was shown to directly bind to OVM, acting as the entry receptor for the virus. The tumor selectivity of OVM was found to be determined by a combination of MXRA8 and the intracellular factor ZAP. This study provides a novel dual-biomarker for precision medicine in OVM therapy.

SIGNAL TRANSDUCTION AND TARGETED THERAPY (2022)

添加到收藏夹

Review Oncology

CRISPR in cancer biology and therapy

Alyna Katti et al.

Summary: Over the past decade, CRISPR has played a crucial role in biomedical research, particularly in cancer research. It has provided new methods for studying cancer and improving diagnosis and treatment.

NATURE REVIEWS CANCER (2022)

添加到收藏夹

Review Chemistry, Multidisciplinary

Small molecule inhibitors targeting the PD-1/PD-L1 signaling pathway

Qian Wu et al.

Summary: PD-1/PD-L1 signaling pathway is a target for anticancer drugs, and the development of small molecule inhibitors provides a new avenue for tumor immunotherapy.

ACTA PHARMACOLOGICA SINICA (2021)

添加到收藏夹

Article Biotechnology & Applied Microbiology

Oncolytic virus promotes tumor-reactive infiltrating lymphocytes for adoptive cell therapy

Mathilde Feist et al.

Summary: The use of oncolytic virus (OV) can stimulate tumor-specific TIL, which show significant therapeutic effects in experiments after expansion, providing a potential option for adoptive cell therapy (ACT) for solid tumors.

CANCER GENE THERAPY (2021)

添加到收藏夹

Review Oncology

Fedratinib, a newly approved treatment for patients with myeloproliferative neoplasm-associated myelofibrosis

Moshe Talpaz et al.

Summary: Myelofibrosis is a serious bone marrow disorder characterized by splenomegaly, and Fedratinib, a selective JAK2 inhibitor, has shown promising results in treating MF patients by targeting the JAK/STAT signaling pathway.

LEUKEMIA (2021)

添加到收藏夹

Article Biology

PD-1 derived CA-170 is an oral immune checkpoint inhibitor that exhibits preclinical anti-tumor efficacy

Pottayil G. Sasikumar et al.

Summary: CA-170 is a small molecule inhibitor that activates T cells and exhibits anti-tumor efficacy in mouse models, advancing to human clinical trials for its potential as an anti-cancer drug.

COMMUNICATIONS BIOLOGY (2021)

添加到收藏夹

Article Oncology

Oncolytic virotherapy-mediated anti-tumor response: a single-cell perspective

Egle Ramelyte et al.

Summary: The study found that intralesional T-VEC treatment in primary cutaneous B cell lymphoma patients led to significant tumor response, rapid eradication of malignant cells, activation of the interferon pathway, and early influx of various immune cells, ultimately resulting in enhanced cellular immunity.

CANCER CELL (2021)

添加到收藏夹

Article Oncology

Stereotactic body radiation combined with oncolytic vaccinia virus induces potent anti-tumor effect by triggering tumor cell necroptosis and DAMPs

Wan-Yu Chen et al.

Summary: The combination of high-dose hypo fractionated stereotactic body radiotherapy (SBRT) and oncolytic vaccinia virus in preclinical murine models showed enhanced anti-tumor effects and altered immune cell infiltration in the tumor microenvironment.

CANCER LETTERS (2021)

添加到收藏夹

Article Biotechnology & Applied Microbiology

The Identification and Development of a Novel Oncolytic Virus: Alphavirus M1

Jing Cai et al.

Summary: Oncolytic virotherapy is an ideal therapeutic platform for cancer that selectively replicates in and destroys tumor cells while sparing normal cells. However, challenges such as the lack of biomarkers for precise treatment, pre-existing neutralizing antibodies to popular oncolytic viral vectors, and immature lyophilization technology hinder the full potential of oncolytic viruses.

HUMAN GENE THERAPY (2021)

添加到收藏夹

Review Chemistry, Medicinal

Research progress of dual inhibitors targeting crosstalk between histone epigenetic modulators for cancer therapy

Ying-Chao Duan et al.

Summary: Abnormal epigenetics is a critical feature of human cancers, and targeting histone epigenetic modulators for anticancer drug discovery has made advances. However, challenges such as limited therapeutic profile, drug resistance, narrow safety margin, and toxicities exist. Co-targeting histone epigenetic modulators with different mechanisms has emerged as an effective strategy to overcome limitations.

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2021)

添加到收藏夹

Article Oncology

Enhanced antitumor immunity by a novel small molecule HPK1 inhibitor

Dan You et al.

Summary: This study identified a novel, potent, and selective HPK1 small molecule kinase inhibitor called Compound K (CompK), which significantly improved human T-cell immune responses in the tumor microenvironment and showed significant synergy with anti-PD-1 therapy. Animal model studies demonstrated improved immune responses and antitumor efficacy with CompK in combination with anti-PD-1, suggesting its potential as a novel pharmacological agent for cancer treatment.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)

添加到收藏夹

Article Oncology

A systemically deliverable Vaccinia virus with increased capacity for intertumoral and intratumoral spread effectively treats pancreatic cancer

Giulia Marelli et al.

Summary: The modified VVL-21 virus showed antitumor efficacy in models of pancreatic cancer after systemic delivery, increasing the number of effector CD8+ T cells and sensitizing tumors to immune checkpoint inhibitors.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)

添加到收藏夹

Article Oncology

IL-36γ-armed oncolytic virus exerts superior efficacy through induction of potent adaptive antitumor immunity

Min Yang et al.

Summary: In this study, IL-36 gamma-armed oncolytic vaccinia viruses demonstrated potent therapeutic efficacy mainly through antitumor immunity, showing great potential to advance treatment in human cancer patients. The mechanism involved the induction of lymphocyte and dendritic cell infiltration, reduction of myeloid-derived suppressor cells and M2-like tumor-associated macrophages, and T cell differentiation into effector cells.

CANCER IMMUNOLOGY IMMUNOTHERAPY (2021)

添加到收藏夹

Article Oncology

Mutations in the IFNγ-JAK-STAT Pathway Causing Resistance to Immune Checkpoint Inhibitors in Melanoma Increase Sensitivity to Oncolytic Virus Treatment

Tan-Trieu Nguyen et al.

Summary: Mutations in the IFN gamma-JAK-STAT pathway have been identified as a resistance mechanism to immune checkpoint inhibitors in a subset of patients with melanoma. Research has shown that melanomas with these mutations may exhibit increased sensitivity to oncolytic virus therapy, providing a potential precision medicine strategy for both salvage therapy in ICI-resistant cases and first-line treatment in melanomas with IFN gamma signaling defects. This study also supports the use of JAK inhibitor-OV combination therapy for treatment-naive melanomas without IFN signaling defects.

CLINICAL CANCER RESEARCH (2021)

添加到收藏夹

Review Biochemistry & Molecular Biology

Epigenetic modulation of antitumor immunity for improved cancer immunotherapy

Enyong Dai et al.

Summary: Epigenetic mechanisms play important roles in cancer initiation and immune cell function, with the potential to impact tumor microenvironment and therapeutic efficacy by modulating immune cell populations and promoting transcriptional and metabolic reprogramming. By regulating immune-associated genes and immune checkpoint molecules, epigenetic modulating agents can enhance tumor immunogenicity and facilitate anti-tumor immune responses.

MOLECULAR CANCER (2021)

添加到收藏夹

Article Medicine, Research & Experimental

ATM inhibition enhances cancer immunotherapy by promoting mtDNA leakage and cGAS/STING activation

Mengjie Hu et al.

Summary: Inhibition of ATM can enhance immune checkpoint blockade therapy by promoting cytoplasmic leakage of mitochondrial DNA and activating the cGAS/STING pathway, delaying tumor growth, enhancing the efficacy of anti-PD-1 therapy, and increasing lymphocyte infiltration into the tumor microenvironment. Additionally, ATM mutations, especially nonsense mutations, can predict clinical benefits of ICB therapy.

JOURNAL OF CLINICAL INVESTIGATION (2021)

添加到收藏夹

Editorial Material Multidisciplinary Sciences

Oncolytic virotherapy as immunotherapy

Alan Melcher et al.

SCIENCE (2021)

添加到收藏夹

Article Multidisciplinary Sciences

An oncolytic virus expressing a full-length antibody enhances antitumor innate immune response to glioblastoma

Bo Xu et al.

Summary: Oncolytic herpes simplex virus-1 can lyse tumor cells and activate the immune system; oncolytic viruses expressing anti-CD47 antibodies can improve the survival of glioblastoma patients.

NATURE COMMUNICATIONS (2021)

添加到收藏夹

Article Immunology

Combining IL-10 and Oncolytic Adenovirus Demonstrates Enhanced Antitumor Efficacy Through CD8+ T Cells

Duo Chen et al.

Summary: Oncolytic viruses combined with interleukin 10 (IL-10) can enhance antitumor efficacy significantly, especially depending on CD8(+) T cells. The combination therapy induced long-term tumor-specific immune memory in a mouse model, rejecting rechallenge by specific tumor cell lines.

FRONTIERS IN IMMUNOLOGY (2021)

添加到收藏夹

Article Oncology

Discovery of a new inhibitor targeting PD-L1 for cancer immunotherapy

Fengling Wang et al.

Summary: The small molecule inhibitor APBC can effectively interrupt the PD-1/PD-L1 interaction, showing promising potential for cancer immunotherapy by enhancing T cell functions. Additionally, APBC demonstrates superior antitumor efficacy in mouse models without inducing observable liver toxicity, making it a promising drug candidate for tumor immunotherapy.

NEOPLASIA (2021)

添加到收藏夹

Article Oncology

A novel vaccinia virus enhances anti-tumor efficacy and promotes a long-term anti-tumor response in a murine model of colorectal cancer

Na Wang et al.

Summary: By arming a novel vaccinia virus with the cytokine interleukin-21, researchers have developed a promising oncolytic virus therapy for the treatment of colorectal cancer. This therapy demonstrated superior anti-tumor efficacy in murine CRC models, primarily mediated by CD8(+) T cells, leading to the development of long-term immunity against tumor cells and prevention of disease recurrence.

MOLECULAR THERAPY-ONCOLYTICS (2021)

添加到收藏夹

Article Oncology

Real-life use of talimogene laherparepvec (T-VEC) in melanoma patients in centers in Austria, Switzerland and Germany

Julia Maria Ressler et al.

Summary: The study assessed the outcomes of 88 melanoma patients treated with T-VEC, showing an overall response rate of 63.7% and 43.2% achieving a complete response. The median treatment period was 19 weeks, with 45.3% of patients experiencing adverse events, mostly mild in nature.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)

添加到收藏夹

Article Oncology

Immunogenic Cell Death by the Novel Topoisomerase I Inhibitor TLC388 Enhances the Therapeutic Efficacy of Radiotherapy

Kevin Chih-Yang Huang et al.

Summary: The study evaluates the induction of immunogenic cell death (ICD) by the novel topoisomerase I inhibitor lipotecan for anticancer immunity. Lipotecan significantly increases tumor immunogenicity and promotes therapeutic efficacy of radiotherapy compared to conventional chemoradiotherapy in vivo. These results suggest potential therapeutic strategies to improve the efficacy of chemoradiotherapy in colorectal cancer patients, particularly those with locally advanced rectal cancer.

CANCERS (2021)

添加到收藏夹

Article Oncology

IL-7 coupled with IL-12 increases intratumoral T cell clonality, leading to complete regression of non-immunogenic tumors

Mamoru Tasaki et al.

Summary: The combination of IL-7 and IL-12 may have potential therapeutic significance in improving intratumoral immune status and increasing tumor regression rates.

CANCER IMMUNOLOGY IMMUNOTHERAPY (2021)

添加到收藏夹

Article Oncology

Enhanced anti-melanoma efficacy through a combination of the armed oncolytic adenovirus ZD55-IL-24 and immune checkpoint blockade in B16-bearing immunocompetent mouse model

Hai-Jun Hu et al.

Summary: The combination therapy of localized ZD55-IL-24 and systemic PD-1 blockade shows a synergistic inhibition of both local and distant established tumors in an immunocompetent mouse model. This synergistic therapeutic effect is associated with the promotion of tumor immune infiltration and recognition, primarily facilitated by ZD55-IL-24 therapy. The study suggests a rationale for further investigation of this combination therapy in clinical settings.

CANCER IMMUNOLOGY IMMUNOTHERAPY (2021)

添加到收藏夹

Article Oncology

Can Biomarkers Guide Oncolytic Virus Immunotherapy?

Howard L. Kaufman

Summary: Defects in tumor cell IFN gamma signaling are linked to resistance to immune checkpoint inhibitors and increased sensitivity to oncolytic virus infection. Differential expression of innate sensing elements in tumor cells may serve as predictive biomarkers for oncolytic virus immunotherapy in cancer patients.

CLINICAL CANCER RESEARCH (2021)

添加到收藏夹

Review Biochemistry & Molecular Biology

PI3K Inhibitors in Cancer: Clinical Implications and Adverse Effects

Rosalin Mishra et al.

Summary: The PI3K pathway is crucial in cancer development and is a promising therapeutic target. Clinical trials are ongoing to evaluate the efficacy and potential risks associated with PI3K inhibitors in overcoming resistance to current therapies.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

添加到收藏夹

Article Oncology

CX-5461 Treatment Leads to Cytosolic DNA-Mediated STING Activation in Ovarian Cancer

Robert Cornelison et al.

Summary: Treatment with CX-5461 leads to the accumulation of cytosolic dsDNA, activating the cGAS-STING-TBK1-IRF3 innate immune pathway and inducing type I interferon production. This immune activation may be a powerful mechanism of action to exploit in novel drug combinations for increasing immunotherapy efficacy and potentially limiting deleterious toxicities with some cancer specificity.

CANCERS (2021)

添加到收藏夹

Review Oncology

Oncolytic viruses encoding bispecific T cell engagers: a blueprint for emerging immunovirotherapies

Johannes P. W. Heidbuechel et al.

Summary: Bispecific T cell engagers (BiTEs) and oncolytic viruses (OVs) are emerging cancer immunotherapies that redirect T cells to tumor surface antigens and selectively infect malignant cells to mediate tumor vaccination effects, respectively. These two approaches can synergize with each other and with other immunotherapies, such as CAR T cells and immune checkpoint inhibitors, to enhance anti-tumor effects.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)

添加到收藏夹

Review Immunology

Resistance Mechanisms Influencing Oncolytic Virotherapy, a Systematic Analysis

Darshak K. Bhatt et al.

Summary: Resistance to oncolytic virotherapy is a significant challenge in cancer treatment, with various mechanisms identified including interferon signaling, epigenetic modifications, and other barriers to viral spread. Further research on therapy resistance and the stromal compartment is necessary for developing more effective treatments using oncolytic viruses.

VACCINES (2021)

添加到收藏夹

Review Pharmacology & Pharmacy

Current developments of targeting the p53 signaling pathway for cancer treatment

Jing Huang

Summary: p53, one of the most well-studied tumor suppressors, is mutated or deleted in half of all cancers. Despite over forty years of research, designing therapeutics targeting the p53 pathway remains extremely challenging. Current efforts include developing p53-based gene therapy and targeted therapies, as well as exploiting the immunogenicity of p53 protein for cancer immunotherapy.

PHARMACOLOGY & THERAPEUTICS (2021)

添加到收藏夹

Review Pharmacology & Pharmacy

AKT Inhibitors: New Weapons in the Fight Against Breast Cancer?

Federica Martorana et al.

Summary: The AKT protein kinase is crucial in breast cancer treatment, especially in resistant subtypes. Several AKT inhibitors are in clinical trials, with new combination strategies being explored to enhance therapeutic efficacy.

FRONTIERS IN PHARMACOLOGY (2021)

添加到收藏夹

Review Immunology

STINGing the Tumor Microenvironment to Promote Therapeutic Tertiary Lymphoid Structure Development

Jessica N. Filderman et al.

Summary: Tertiary lymphoid structures (TLS) are unique lymphoid tissues that conditionally form in peripheral tissues in a milieu of sustained inflammation, serving as regional sites for induction and expansion of the host B and T cell repertoires. Therapeutic strategies targeting DC, VEC, and local cytokine/chemokine profiles actively promote TLS formation and the development of an inflammatory tumor microenvironment.

FRONTIERS IN IMMUNOLOGY (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Discovery of 1,3,4-oxadiazole derivatives as potential antitumor agents inhibiting the programmed cell death-1/programmed cell death-ligand 1 interaction

Lincheng Fang et al.

Summary: The novel 1,3,4-oxadiazole derivative II-14 effectively inhibits the PD-1/PD-L1 interaction, showing significant efficacy in a mouse tumor model and potential synergistic effects when combined with 5-FU.

BIOORGANIC & MEDICINAL CHEMISTRY (2021)

添加到收藏夹

Article Hematology

Pacritinib protects dendritic cells more efficiently than ruxolitinib

Annkristin Heine et al.

Summary: Targeting JAK has revolutionized the treatment of myeloproliferative neoplasms, with the JAK inhibitor ruxolitinib significantly improving patient outcomes at the cost of increased infection risk. The novel JAK inhibitor pacritinib exhibits less pronounced immunosuppressive effects on dendritic cells compared to ruxolitinib, providing a potentially promising treatment option for patients with myelofibrosis.

EXPERIMENTAL HEMATOLOGY (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Oncolytic Bovine Herpesvirus 1 Inhibits Human Lung Adenocarcinoma A549 Cell Proliferation and Tumor Growth by Inducing DNA Damage

Wencai Qiu et al.

Summary: The study demonstrates that BoHV-1 has oncolytic effects against human lung adenocarcinoma in vivo. BoHV-1 infection reduced HDAC protein levels in A549 cells and showed synergy with the HDAC inhibitor TSA. In the mouse xenograft model, BoHV-1 effectively infected tumors and suppressed tumor growth, potentially through interaction with HDACs.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

添加到收藏夹

Review Oncology

Evolving therapeutic landscape in follicular lymphoma: a look at emerging and investigational therapies

Walter Hanel et al.

Summary: Follicular Lymphoma (FL) is the most common subtype of indolent B cell non-Hodgkin lymphoma with heterogeneous clinical courses. Treatment options for FL include chemotherapy, immunotherapy, targeted therapy, and cellular therapy. Multiple combination therapies are currently in clinical trials, offering promising new treatment options for patients with FL.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Novel induction of CD40 expression by tumor cells with RAS/RAF/PI3K pathway inhibition augments response to checkpoint blockade

Chi Yan et al.

Summary: The study identified that Rigosertib (RGS) can sensitize melanoma tumors to immune checkpoint blockade therapy by modulating immune cells in the tumor microenvironment, leading to tumor growth inhibition. Results suggest that RGS treatment induces immunogenic cell death in melanoma cells and upregulates CD40 expression, enhancing beneficial T-cell responses and improving patient survival. This indicates the potential therapeutic use of RGS in combination with immune checkpoint blockade for melanoma patients who do not respond to immune checkpoint blockade alone.

MOLECULAR CANCER (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Discovery of Novel Small-Molecule Inhibitors of PD-1/PD-L1 Interaction via Structural Simplification Strategy

Hongbo Zhang et al.

Summary: The blockade of the PD-1/PD-L1 interaction is a major focus in cancer immunotherapy, with several monoclonal antibodies showing promising outcomes. However, limitations with mAbs have led to the development of small-molecule inhibitors of PD-1/PD-L1 pathways. A new series of inhibitors targeting the PD-1/PD-L1 interaction have been discovered, with compound A9 showing the most promising inhibitory activity and binding affinity, as well as the ability to promote the production of interferon-gamma.

MOLECULES (2021)

添加到收藏夹

Article Cell Biology

A small-molecule SUMOylation inhibitor activates antitumor immune responses and potentiates immune therapies in preclinical models

Eric S. Lightcap et al.

Summary: TAK-981 is a first-in-class SUMOylation inhibitor that promotes antitumor immune responses by activating IFN1 signaling. Studies have shown that TAK-981 inhibits tumor growth in mice, dependent on IFN1 signaling and CD8(+) T cells, and is associated with increased intratumoral T and natural killer cell number and activation.

SCIENCE TRANSLATIONAL MEDICINE (2021)

添加到收藏夹

Article Cell Biology

An MDM2 inhibitor achieves synergistic cytotoxic effects with adenoviruses lacking E1B55kDa gene on mesothelioma with the wild-type p53 through augmenting NFI expression

Thao Thi Thanh Nguyen et al.

Summary: The study demonstrated that the combination of MDM2 inhibitors with p53-activating Ad-delE1B produced synergistic inhibitory effects on mesothelioma with wild-type p53 genotype. The combination enhanced p53 phosphorylation, activated apoptotic pathway, and increased DNA damage signals through ATM-Chk2 phosphorylation. MDM2 inhibitors facilitated Ad production through NFI induction, suggesting a therapeutic strategy for p53 wild-type mesothelioma with replicative Ad and elevated p53 levels.

CELL DEATH & DISEASE (2021)

添加到收藏夹

Article Chemistry, Multidisciplinary

Multifunctional Nanodrug Mediates Synergistic Photodynamic Therapy and MDSCs-Targeting Immunotherapy of Colon Cancer

Dongbing Ding et al.

Summary: By combining immunogenic photodynamic therapy with MDSC-targeting immunotherapy, the synergistic treatment effectively inhibits tumor growth while promoting immune responses to prevent tumor recurrence and metastasis.

ADVANCED SCIENCE (2021)

添加到收藏夹

Article Oncology

High potency STING agonists engage unique myeloid pathways to reverse pancreatic cancer immune privilege

Casey R. Ager et al.

Summary: This study demonstrates that high-potency STING agonists can repolarize suppressive myeloid populations and enhance sensitivity of pancreatic adenocarcinoma to immune checkpoint blockade therapy. The findings provide insights into the unique pathways engaged by CDNs in functional repolarization.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)

添加到收藏夹

Review Oncology

Oncolytic Viruses in Combination Therapeutic Approaches with Epigenetic Modulators: Past, Present, and Future Perspectives

Annalisa Chianese et al.

Summary: Cancer rates have been increasing significantly, leading to a need for new treatments. Combining oncolytic viruses with epigenetic modulators shows promise in enhancing immune response and viral effectiveness. Clinical trials and research continue to explore novel therapies for cancer treatment.

CANCERS (2021)

添加到收藏夹

Review Oncology

Combining Oncolytic Viruses and Small Molecule Therapeutics: Mutual Benefits

Bart Spiesschaert et al.

Summary: Combinations of oncolytic viruses with specific small molecule compounds can help overcome limitations in their ability to replicate and kill tumors in clinical settings. This review focuses on mechanisms by which small molecules can synergize with oncolytic viruses to enhance viral replication, tumor cell killing, and antitumor immune responses.

CANCERS (2021)

添加到收藏夹

Review Cell Biology

Role of Small Molecule Targeted Compounds in Cancer: Progress, Opportunities, and Challenges

Guoqiang Sun et al.

Summary: Research on molecular targeted therapy of tumors is thriving, with novel targeted therapy drugs constantly emerging. Small molecule targeted compounds can be administered orally, do not elicit immune response, and are cost-effective, making them a hot topic in tumor treatment research.

FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2021)

添加到收藏夹

Review Biochemistry & Molecular Biology

Targeting PI3K/Akt signal transduction for cancer therapy

Yan He et al.

Summary: The PI3K/Akt signaling pathway plays a crucial role in cancer, and targeting inhibitors against it may aid in drug discovery. Additionally, combining pathway inhibitors with other cancer treatment strategies could be an effective approach to solving therapeutic dilemmas.

SIGNAL TRANSDUCTION AND TARGETED THERAPY (2021)

添加到收藏夹

Review Biochemistry & Molecular Biology

KRAS mutation: from undruggable to druggable in cancer

Lamei Huang et al.

Summary: This review provides the latest understanding of fundamental aspects of KRAS, the relationship between KRAS mutations and tumor immune evasion, and new progress in targeting KRAS, particularly KRAS (G12C). The possible mechanisms of resistance to KRAS (G12C) inhibitors and potential combination therapies are also summarized, aiming to offer the best personalized treatment regimen with KRAS (G12C) inhibitors and achieve truly precise treatment.

SIGNAL TRANSDUCTION AND TARGETED THERAPY (2021)

添加到收藏夹

Letter Biochemistry & Molecular Biology

Modulating the tumor microenvironment via oncolytic virus and PI3K inhibition synergistically restores immune checkpoint therapy response in PTEN-deficient glioblastoma

Fan Xing et al.

SIGNAL TRANSDUCTION AND TARGETED THERAPY (2021)

添加到收藏夹

Review Oncology

Cancer metabolism: looking forward

Inmaculada Martinez-Reyes et al.

Summary: This Perspective discusses the main themes in cancer metabolism research, focusing on the relationship between tumour initiation and progression with metabolic reprogramming, as well as the importance of tumor microenvironment and metabolic regulation.

NATURE REVIEWS CANCER (2021)

添加到收藏夹

Review Biochemistry & Molecular Biology

Small molecules in targeted cancer therapy: advances, challenges, and future perspectives

Lei Zhong et al.

Summary: Targeted therapeutic drugs have become mainstream cancer treatments due to their advantages in efficacy and safety, but still face challenges such as low response rate and drug resistance. A comprehensive review was conducted on small-molecule targeted anti-cancer drugs to promote their development, discussing current challenges and providing insights and perspectives for future research and development.

SIGNAL TRANSDUCTION AND TARGETED THERAPY (2021)

添加到收藏夹

Review Medicine, Research & Experimental

Turning cold tumors into hot tumors by improving T-cell infiltration

Yuan-Tong Liu et al.

Summary: Immunotherapy, particularly through immune checkpoint inhibitors, has significantly improved the treatment of malignant tumors by enhancing T cell infiltration into tumors. Understanding the mechanisms underlying cold tumors, which lack T cell infiltration, is crucial to improving immunotherapy efficacy. Strategies to transform cold tumors into hot tumors and increase T cell infiltration are discussed, along with the potential of nanomedicines in enhancing tumor immunotherapy.

THERANOSTICS (2021)

添加到收藏夹

Review Oncology

Systemic immunity in cancer

Kamir J. Hiam-Galvez et al.

Summary: Understanding systemic immune landscape beyond the tumour microenvironment is crucial in assessing the effectiveness of immunotherapy in cancer treatment. Despite the potential of immunotherapy to induce new immune responses, compromised immune responses in individuals with tumors may limit its efficacy.

NATURE REVIEWS CANCER (2021)

添加到收藏夹

Article Oncology

IL-21 arming potentiates the anti-tumor activity of an oncolytic vaccinia virus in monotherapy and combination therapy

Tianyue Chen et al.

Summary: Through this study, IL-21 and TTV were identified as the most potent immunomodulatory molecule and oncolytic virus for solid tumor suppression in mouse models. A novel recombinant oncolytic virus resulting from their combination, namely rTTV Delta TK-mIL21, showed significant anti-tumor activity in mice.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)

添加到收藏夹

Article Medicine, Research & Experimental

Intratumoral expression of interleukin 23 variants using oncolytic vaccinia virus elicit potent antitumor effects on multiple tumor models via tumor microenvironment modulation

Lingjuan Chen et al.

Summary: Armed with IL-23 variants, oncolytic vaccinia viruses can enhance anti-tumor immune responses, transforming the tumor microenvironment to be more favorable for anti-tumor effects.

THERANOSTICS (2021)

添加到收藏夹

Review Oncology

The emerging role of epigenetic therapeutics in immuno-oncology

Michael J. Topper et al.

NATURE REVIEWS CLINICAL ONCOLOGY (2020)

添加到收藏夹

Article Cell Biology

Temozolomide induces activation of Wnt/β-catenin signaling in glioma cells via PI3K/Akt pathway: implications in glioma therapy

Vivek Singh Tomar et al.

CELL BIOLOGY AND TOXICOLOGY (2020)

添加到收藏夹

Article Oncology

Synergistic Combination of Oncolytic Virotherapy and Immunotherapy for Glioma

Bingtao Tang et al.

CLINICAL CANCER RESEARCH (2020)

添加到收藏夹

Review Cell Biology

Janus kinase inhibitors: A therapeutic strategy for cancer and autoimmune diseases

Arezoo Hosseini et al.

JOURNAL OF CELLULAR PHYSIOLOGY (2020)

添加到收藏夹

Article Oncology

A phase I/II study of Pexa-Vec oncolytic virus in combination with immune checkpoint inhibition in refractory colorectal cancer.

M. Cecilia Monge B. et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

添加到收藏夹

Article Chemistry, Medicinal

Discovery of a Covalent Inhibitor of KRASG12C (AMG 510) for the Treatment of Solid Tumors

Brian A. Lanman et al.

JOURNAL OF MEDICINAL CHEMISTRY (2020)

添加到收藏夹

Article Oncology

Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial

Robert H. Jones et al.

LANCET ONCOLOGY (2020)

添加到收藏夹

Article Oncology

Macrophage Syk-PI3Kγ Inhibits Antitumor Immunity: SRX3207, a Novel Dual Syk-PI3K Inhibitory Chemotype Relieves Tumor Immunosuppression

Shweta Joshi et al.

MOLECULAR CANCER THERAPEUTICS (2020)

添加到收藏夹

Article Biotechnology & Applied Microbiology

Transient Inhibition of PI3Kδ Enhances the Therapeutic Effect of Intravenous Delivery of Oncolytic Vaccinia Virus

Mark S. Ferguson et al.

MOLECULAR THERAPY (2020)

添加到收藏夹

Review Pharmacology & Pharmacy

Targeting SHP2 as a promising strategy for cancer immunotherapy

Qianqian Liu et al.

PHARMACOLOGICAL RESEARCH (2020)

添加到收藏夹

Article Cell Biology

Intratumoral expression of IL-7 and IL-12 using an oncolytic virus increases systemic sensitivity to immune checkpoint blockade

Shinsuke Nakao et al.

SCIENCE TRANSLATIONAL MEDICINE (2020)

添加到收藏夹

Article Cell Biology

Characterization of virus-mediated immunogenic cancer cell death and the consequences for oncolytic virus-based immunotherapy of cancer

Jing Ma et al.

CELL DEATH & DISEASE (2020)

添加到收藏夹

Review Pharmacology & Pharmacy

Small-molecule MDM2/X inhibitors and PROTAC degraders for cancer therapy: advances and perspectives

Yuan Fang et al.

ACTA PHARMACEUTICA SINICA B (2020)

添加到收藏夹

Review Cell Biology

The future of cancer immunotherapy: microenvironment-targeting combinations

Yonina R. Murciano-Goroff et al.

CELL RESEARCH (2020)

添加到收藏夹

Article Oncology

Intratumoral Delivery of a PD-1-Blocking scFv Encoded in Oncolytic HSV-1 Promotes Antitumor Immunity and Synergizes with TIGIT Blockade

Chaolong Lin et al.

CANCER IMMUNOLOGY RESEARCH (2020)

添加到收藏夹

Review Biochemistry & Molecular Biology

P53: A Guardian of Immunity Becomes Its Saboteur through Mutation

Arjelle Decasa Agupitan et al.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)

添加到收藏夹

Article Medicine, Research & Experimental

Epigenetic driver mutations in ARID1A shape cancer immune phenotype and immunotherapy

Jing Li et al.

JOURNAL OF CLINICAL INVESTIGATION (2020)

添加到收藏夹

Review Multidisciplinary Sciences

Metabolic reprogramming and cancer progression

Brandon Faubert et al.

SCIENCE (2020)

添加到收藏夹

Review Immunology

Immunotherapeutic Potential of TGF-β Inhibition and Oncolytic Viruses

Christianne Groeneveldt et al.

TRENDS IN IMMUNOLOGY (2020)

添加到收藏夹

Article Multidisciplinary Sciences

An engineered oncolytic virus expressing PD-L1 inhibitors activates tumor neoantigen-specific T cell responses

Guan Wang et al.

NATURE COMMUNICATIONS (2020)

添加到收藏夹

Article Medicine, General & Internal

Small molecules, big impact: 20 years of targeted therapy in oncology

Philippe L Bedard et al.

LANCET (2020)

添加到收藏夹

Review Immunology

The Tumor Microenvironment: A Milieu Hindering and Obstructing Antitumor Immune Responses

Alireza Labani-Motlagh et al.

FRONTIERS IN IMMUNOLOGY (2020)

添加到收藏夹

Article Oncology

Oncolytic vaccinia virus delivering tethered IL-12 enhances antitumor effects with improved safety

Yan Ge et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)

添加到收藏夹

Article Oncology

Temozolomide antagonizes oncolytic immunovirotherapy in glioblastoma

Dipongkor Saha et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)

添加到收藏夹

Review Pharmacology & Pharmacy

Small molecules targeting the innate immune cGAS-STING-TBK1 signaling pathway

Chunyong Ding et al.

ACTA PHARMACEUTICA SINICA B (2020)

添加到收藏夹

Review Biochemistry & Molecular Biology

Bi- and Tri-Specific T Cell Engager-Armed Oncolytic Viruses: Next-Generation Cancer Immunotherapy

Zong Sheng Guo et al.

BIOMEDICINES (2020)

添加到收藏夹

Review Oncology

cGAS-STING, an important pathway in cancer immunotherapy

Minlin Jiang et al.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)

添加到收藏夹

Review Oncology

Oncolytic viruses for cancer immunotherapy

Otto Hemminki et al.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)

添加到收藏夹

Review Immunology

The Contribution of Epigenetics to Cancer Immunotherapy

Lorea Villanueva et al.

TRENDS IN IMMUNOLOGY (2020)

添加到收藏夹

Article Chemistry, Medicinal

Di-bromo-Based Small-Molecule Inhibitors of the PD-1/PD-L1 Immune Checkpoint

Magdalena Konieczny et al.

JOURNAL OF MEDICINAL CHEMISTRY (2020)

添加到收藏夹

Article Chemistry, Medicinal

Identification of TNO155, an Allosteric SHP2 Inhibitor for the Treatment of Cancer

Matthew J. LaMarche et al.

JOURNAL OF MEDICINAL CHEMISTRY (2020)

添加到收藏夹

Review Biochemistry & Molecular Biology

Targeting STAT3 in Cancer Immunotherapy

Sailan Zou et al.

MOLECULAR CANCER (2020)

添加到收藏夹

Review Biochemistry & Molecular Biology

Comprehensive elaboration of the cGAS-STING signaling axis in cancer development and immunotherapy

Juyan Zheng et al.

MOLECULAR CANCER (2020)

添加到收藏夹

Article Oncology

Tumors driven by RAS signaling harbor a natural vulnerability to oncolytic virus M1

Jing Cai et al.

MOLECULAR ONCOLOGY (2020)

添加到收藏夹

Review Biotechnology & Applied Microbiology

Targeting the epigenetic regulation of antitumour immunity

Simon J. Hogg et al.

NATURE REVIEWS DRUG DISCOVERY (2020)

添加到收藏夹

Article Medicine, General & Internal

KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors

David S. Hong et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Review Oncology

Clinical landscape of oncolytic virus research in 2020

Nicholas Macedo et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)

添加到收藏夹

Article Oncology

Integrity of the Antiviral STING-mediated DNA Sensing in Tumor Cells Is Required to Sustain the Immunotherapeutic Efficacy of Herpes Simplex Oncolytic Virus

Guendalina Froechlich et al.

CANCERS (2020)

添加到收藏夹

Article Oncology

IL-24-Armed Oncolytic Vaccinia Virus Exerts Potent Antitumor Effects via Multiple Pathways in Colorectal Cancer

Lili Deng et al.

ONCOLOGY RESEARCH (2020)

添加到收藏夹

Review Biochemistry & Molecular Biology

Improving antitumor efficacy via combinatorial regimens of oncolytic virotherapy

Bin Zhang et al.

MOLECULAR CANCER (2020)

添加到收藏夹

Article Hematology

Resistance to histone deacetylase inhibitors confers hypersensitivity to oncolytic reovirus therapy

Shariful Islam et al.

BLOOD ADVANCES (2020)

添加到收藏夹

Review Oncology

Clinical Development of BRAF plus MEK Inhibitor Combinations

Vivek Subbiah et al.

TRENDS IN CANCER (2020)

添加到收藏夹

Article Biochemistry & Molecular Biology

SnapShot: Cancer Immunotherapy with Oncolytic Viruses

Shashi Gujar et al.

CELL (2019)

添加到收藏夹

Review Biochemistry & Molecular Biology

Targeting PI3K in cancer: mechanisms and advances in clinical trials

Jing Yang et al.

MOLECULAR CANCER (2019)

添加到收藏夹

Article Biochemistry & Molecular Biology

Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma

Junfei Zhao et al.

NATURE MEDICINE (2019)

添加到收藏夹

Review Oncology

The Antiviral Apparatus: STING and Oncolytic Virus Restriction

Joel Lee et al.

MOLECULAR THERAPY-ONCOLYTICS (2019)

添加到收藏夹

Review Oncology

Oncolytic Virus-Based Cytokine Expression to Improve Immune Activity in Brain and Solid Tumors

Taylor M. Pearl et al.

MOLECULAR THERAPY-ONCOLYTICS (2019)

添加到收藏夹

Article Oncology

Oncolytic Herpes Simplex Virus and PI3K Inhibitor BKM120 Synergize to Promote Killing of Prostate Cancer Stem-like Cells

Lei Wang et al.

MOLECULAR THERAPY-ONCOLYTICS (2019)

添加到收藏夹

Article Oncology

Targeting the tumor stroma with an oncolytic adenovirus secreting a fibroblast activation protein-targeted bispecific T-cell engager

Jana de Sostoa et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)

添加到收藏夹

Review Biochemistry & Molecular Biology

Targeting PI3K signaling in cancer: Challenges and advances

Maria Chiara De Santis et al.

BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER (2019)

添加到收藏夹

Article Virology

SIRT1 Modulates the Sensitivity of Prostate Cancer Cells to Vesicular Stomatitis Virus Oncolysis

Michela Muscolini et al.

JOURNAL OF VIROLOGY (2019)

添加到收藏夹

Article Oncology

A Rationally Designed Peptide Antagonist of the PD-1 Signaling Pathway as an Immunomodulatory Agent for Cancer Therapy

Pottayil G. Sasikumar et al.

MOLECULAR CANCER THERAPEUTICS (2019)

添加到收藏夹

Article Biotechnology & Applied Microbiology

Potentiating Oncolytic Virus-Induced Immune-Mediated Tumor Cell Killing Using Histone Deacetylase Inhibition

Victoria A. Jennings et al.

MOLECULAR THERAPY (2019)

添加到收藏夹

Article Medicine, General & Internal

Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer

Fabrice Andre et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

添加到收藏夹

Article Virology

Histone Deacetylase Inhibitors Enhance Cell Killing and Block Interferon-Beta Synthesis Elicited by Infection with an Oncolytic Parainfluenza Virus

Candace R. Fox et al.

VIRUSES-BASEL (2019)

添加到收藏夹

Article Oncology

Oncolytic virus immunotherapy induces immunogenic cell death and overcomes STING deficiency in melanoma

Praveen K. Bommareddy et al.

ONCOIMMUNOLOGY (2019)

添加到收藏夹

Article Neurosciences

Delta-24-RGD combined with radiotherapy exerts a potent antitumor effect in diffuse intrinsic pontine glioma and pediatric high grade glioma models

Naiara Martinez-Velez et al.

ACTA NEUROPATHOLOGICA COMMUNICATIONS (2019)

添加到收藏夹

Review Cell Biology

Immunogenic cell death in cancer therapy: Present and emerging inducers

Jingyi Zhou et al.

JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2019)

添加到收藏夹

Review Oncology

Targeting mTOR for cancer therapy

Hui Hua et al.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)

添加到收藏夹

Article Multidisciplinary Sciences

Loss of p53 triggers WNT-dependent systemic inflammation to drive breast cancer metastasis

Max D. Wellenstein et al.

NATURE (2019)

添加到收藏夹

Review Biotechnology & Applied Microbiology

Optimizing oncolytic virotherapy in cancer treatment

Kevin Harrington et al.

NATURE REVIEWS DRUG DISCOVERY (2019)

添加到收藏夹

Review Genetics & Heredity

DNA sensing by the cGAS-STING pathway in health and disease

Mona Motwani et al.

NATURE REVIEWS GENETICS (2019)

添加到收藏夹

Review Oncology

PI3K/Akt/mTOR inhibitors in cancer: At the bench and bedside

Ali S. Alzahrani

SEMINARS IN CANCER BIOLOGY (2019)

添加到收藏夹

Article Multidisciplinary Sciences

Crizotinib-induced immunogenic cell death in non-small cell lung cancer

Peng Liu et al.

NATURE COMMUNICATIONS (2019)

添加到收藏夹

Article Oncology

Combination of Cetuximab and Oncolytic Virus Canerpaturev Synergistically Inhibits Human Colorectal Cancer Growth

Zhiwen Wu et al.

MOLECULAR THERAPY-ONCOLYTICS (2019)

添加到收藏夹

Article Oncology

Coxsackievirus Type B3 Is a Potent Oncolytic Virus against KRAS-Mutant Lung Adenocarcinoma

Haoyu Deng et al.

MOLECULAR THERAPY-ONCOLYTICS (2019)

添加到收藏夹

Review Oncology

Oncolytic Viruses and Immune Checkpoint Inhibition: The Best of Both Worlds

Venkatesh Sivanandam et al.

MOLECULAR THERAPY-ONCOLYTICS (2019)

添加到收藏夹

Article Oncology

Oncolytic Maraba virus armed with tumor antigen boosts vaccine priming and reveals diverse therapeutic response patterns when combined with checkpoint blockade in ovarian cancer

A. J. Robert McGray et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)

添加到收藏夹

Review Biochemistry & Molecular Biology

Molecular basis for class side effects associated with PI3K/AKT/mTOR pathway inhibitors

Ying Zhang et al.

EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2019)

添加到收藏夹

Article Oncology

STING Restricts oHSV Replication and Spread in Resistant MPNSTs but Is Dispensable for Basal IFN-Stimulated Gene Upregulation

Joel M. Lee et al.

MOLECULAR THERAPY-ONCOLYTICS (2019)

添加到收藏夹

Review Oncology

Small molecule immunomodulation: the tumor microenvironment and overcoming immune escape

Arsen Osipov et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)

添加到收藏夹

Article Medicine, Research & Experimental

Antitumor activity of the PD-1/PD-L1 binding inhibitor BMS-202 in the humanized MHC-double knockout NOG mouse

Tadashi Ashizawa et al.

BIOMEDICAL RESEARCH-TOKYO (2019)

添加到收藏夹

Article Oncology

A Potent and Selective Small-Molecule Degrader of STAT3 Achieves Complete Tumor Regression In Vivo

Longchuan Bai et al.

CANCER CELL (2019)

添加到收藏夹

Article Multidisciplinary Sciences

The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity

Jude Canon et al.

NATURE (2019)

添加到收藏夹

Article Multidisciplinary Sciences

Comprehensive in vitro characterization of PD-L1 small molecule inhibitors

Aravindhan Ganesan et al.

SCIENTIFIC REPORTS (2019)

添加到收藏夹

Article Biotechnology & Applied Microbiology

JAK/STAT inhibition with ruxolitinib enhances oncolytic virotherapy in non-small cell lung cancer models

Manish R. k Patel et al.

CANCER GENE THERAPY (2019)

添加到收藏夹

Review Biochemistry & Molecular Biology

Mutant p53 as a guardian of the cancer cell

Fiamma Mantovani et al.

CELL DEATH AND DIFFERENTIATION (2019)

添加到收藏夹

Review Immunology

The Next Generation of Immunotherapy for Cancer: Small Molecules Could Make Big Waves

William G. Kerr et al.

JOURNAL OF IMMUNOLOGY (2019)

添加到收藏夹

Article Biotechnology & Applied Microbiology

Modulating the Tumor Microenvironment via Oncolytic Viruses and CSF-1R Inhibition Synergistically Enhances Anti-PD-1 Immunotherapy

Gang Shi et al.

MOLECULAR THERAPY (2019)

添加到收藏夹

Article Biochemistry & Molecular Biology

HIP1R targets PD-L1 to lysosomal degradation to alter T cell-mediated cytotoxicity

Huanbin Wang et al.

NATURE CHEMICAL BIOLOGY (2019)

添加到收藏夹

Article Biochemistry & Molecular Biology

Translation control of the immune checkpoint in cancer and its therapeutic targeting

Yichen Xu et al.

NATURE MEDICINE (2019)

添加到收藏夹

Review Pharmacology & Pharmacy

Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers

Robert Roskoski

PHARMACOLOGICAL RESEARCH (2019)

添加到收藏夹

Article Multidisciplinary Sciences

Targeting REGNASE-1 programs long-lived effector T cells for cancer therapy

Jun Wei et al.

NATURE (2019)

添加到收藏夹

Review Oncology

Vaccinia virus-mediated cancer immunotherapy: cancer vaccines and oncolytics

Zong Sheng Guo et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)

添加到收藏夹

Review Cell Biology

Inhibition of p53 inhibitors: progress, challenges and perspectives

Gema Sanz et al.

JOURNAL OF MOLECULAR CELL BIOLOGY (2019)

添加到收藏夹

Review Oncology

Epigenetic therapy in immune-oncology

Peter A. Jones et al.

NATURE REVIEWS CANCER (2019)

添加到收藏夹

Article Oncology

A cautionary note on the selectivity of oncolytic poxviruses

Bingtao Tang et al.

ONCOLYTIC VIROTHERAPY (2019)

添加到收藏夹

Review Oncology

Therapeutically exploiting STAT3 activity in cancer - using tissue repair as a road map

Jennifer Huynh et al.

NATURE REVIEWS CANCER (2019)

添加到收藏夹

Review Oncology

Tumour heterogeneity and resistance to cancer therapies

Ibiayi Dagogo-Jack et al.

NATURE REVIEWS CLINICAL ONCOLOGY (2018)

添加到收藏夹

Article Oncology

An open label, single-arm, phase II multicenter study of the safety and efficacy of CG0070 oncolytic vector regimen in patients with BCG-unresponsive non muscle-invasive bladder cancer: Interim results

Vignesh T. Packiam et al.

UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2018)

添加到收藏夹

Review Oncology

Oncolytic Viruses as Antigen-Agnostic Cancer Vaccines

Stephen J. Russell et al.

CANCER CELL (2018)

添加到收藏夹

Article Oncology

Combinatorial Effects of VEGFR Kinase Inhibitor Axitinib and Oncolytic Virotherapy in Mouse and Human Glioblastoma Stem-Like Cell Models

Dipongkor Saha et al.

CLINICAL CANCER RESEARCH (2018)

添加到收藏夹

Review Biotechnology & Applied Microbiology

Oncolytic Viruses for Tumor Precision Imaging and Radiotherapy

Zi J. Wu et al.

HUMAN GENE THERAPY (2018)

添加到收藏夹

Article Immunology

Activation of p53 in Immature Myeloid Precursor Cells Controls Differentiation into Ly6c+CD103+ Monocytic Antigen-Presenting Cells in Tumors

Madhav D. Sharma et al.

IMMUNITY (2018)

添加到收藏夹

Article Medicine, Research & Experimental

Dinaciclib induces immunogenic cell death and enhances anti-PD1-mediated tumor suppression

Dewan Md Sakib Hossain et al.

JOURNAL OF CLINICAL INVESTIGATION (2018)

添加到收藏夹

Article Oncology

Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma

Jason Chesney et al.

JOURNAL OF CLINICAL ONCOLOGY (2018)

添加到收藏夹

Review Biotechnology & Applied Microbiology

Oncolytic Virus Combination Therapy: Killing One Bird with Two Stones

Nikolas Tim Martin et al.

MOLECULAR THERAPY (2018)

添加到收藏夹

Article Biotechnology & Applied Microbiology

Multi-modal Potentiation of Oncolytic Virotherapy by Vanadium Compounds

Mohammed Selman et al.

MOLECULAR THERAPY (2018)

添加到收藏夹

Article Biotechnology & Applied Microbiology

Superagonist IL-15-Armed Oncolytic Virus Elicits Potent Antitumor Immunity and Therapy That Are Enhanced with PD-1 Blockade

Stacy J. Kowalsky et al.

MOLECULAR THERAPY (2018)

添加到收藏夹

Review Oncology

Targeting the IL-6/JAK/STAT3 signalling axis in cancer

Daniel E. Johnson et al.

NATURE REVIEWS CLINICAL ONCOLOGY (2018)

添加到收藏夹

Article Cell Biology

Dimethyl fumarate potentiates oncolytic virotherapy through NF-kappa B inhibition

Mohammed Selman et al.

SCIENCE TRANSLATIONAL MEDICINE (2018)

添加到收藏夹

Article Cell Biology

The CDK4/6 Inhibitor Abemaciclib Induces a T Cell Inflamed Tumor Microenvironment and Enhances the Efficacy of PD-L1 Checkpoint Blockade

David A. Schaer et al.

CELL REPORTS (2018)

添加到收藏夹

Editorial Material Oncology

Heating it up: Oncolytic viruses make tumors hot' and suitable for checkpoint blockade immunotherapies

Shashi Gujar et al.

ONCOIMMUNOLOGY (2018)

添加到收藏夹

Review Medicine, General & Internal

Lighting a Fire in the Tumor Microenvironment Using Oncolytic Immunotherapy

Carole Achard et al.

EBIOMEDICINE (2018)

添加到收藏夹

Review Oncology

Organoid technology and applications in cancer research

Hanxiao Xu et al.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2018)

添加到收藏夹

Article Biochemistry & Molecular Biology

Metformin Promotes Antitumor Immunity via Endoplasmic-Reticulum-Associated Degradation of PD-L1

Jong-Ho Cha et al.

MOLECULAR CELL (2018)

添加到收藏夹

Review Virology

Defects in interferon pathways as potential biomarkers of sensitivity to oncolytic viruses

Olga V. Matveeva et al.

REVIEWS IN MEDICAL VIROLOGY (2018)

添加到收藏夹

Review Oncology

Fundamental Mechanisms of Immune Checkpoint Blockade Therapy

Spencer C. Wei et al.

CANCER DISCOVERY (2018)

添加到收藏夹

Article Microbiology

Active-site mTOR inhibitors augment HSV1-dICP0 infection in cancer cells via dysregulated eIF4E/4E-BP axis

Chadi Zakaria et al.

PLOS PATHOGENS (2018)

添加到收藏夹

Editorial Material Oncology

The 2018 Nobel Prize in medicine goes to cancer immunotherapy (editorial for BMC cancer)

Zong Sheng Guo

BMC CANCER (2018)

添加到收藏夹

Article Oncology

An Oncolytic Virus Expressing a T-cell Engager Simultaneously Targets Cancer and Immunosuppressive Stromal Cells

Joshua D. Freedman et al.

CANCER RESEARCH (2018)

添加到收藏夹

Article Cell Biology

MEK inhibition enhances oncolytic virus immunotherapy through increased tumor cell killing and T cell activation

Praveen K. Bommareddy et al.

SCIENCE TRANSLATIONAL MEDICINE (2018)

添加到收藏夹

Article Multidisciplinary Sciences

Modifying the cancer-immune set point using vaccinia virus expressing re-designed interleukin-2

Zuqiang Liu et al.

NATURE COMMUNICATIONS (2018)

添加到收藏夹

Article Multidisciplinary Sciences

DNA-PK inhibition synergizes with oncolytic virus M1 by inhibiting antiviral response and potentiating DNA damage

Xiao Xiao et al.

NATURE COMMUNICATIONS (2018)

添加到收藏夹

Review Pharmacology & Pharmacy

Evolution of Cancer Pharmacological Treatments at the Turn of the Third Millennium

Luca Falzone et al.

FRONTIERS IN PHARMACOLOGY (2018)

添加到收藏夹

Review Oncology

Oncolytic viruses as engineering platforms for combination immunotherapy

Kwame Twumasi-Boateng et al.

NATURE REVIEWS CANCER (2018)

添加到收藏夹

Review Immunology

Epigenetic control of CD8+ T cell differentiation

Amanda N. Henning et al.

NATURE REVIEWS IMMUNOLOGY (2018)

添加到收藏夹

Article Oncology

Amplification of Oncolytic Vaccinia Virus Widespread Tumor Cell Killing by Sunitinib through Multiple Mechanisms

Minah Kim et al.

CANCER RESEARCH (2018)

添加到收藏夹

Review Immunology

Integrating oncolytic viruses in combination cancer immunotherapy

Praveen K. Bommareddy et al.

NATURE REVIEWS IMMUNOLOGY (2018)

添加到收藏夹

Article Oncology

The STAT3 inhibitor pyrimethamine displays anti-cancer and immune stimulatory effects in murine models of breast cancer

Mohammad W. Khan et al.

CANCER IMMUNOLOGY IMMUNOTHERAPY (2018)

添加到收藏夹

Article Oncology

Blockade of transforming growth factor-β signaling enhances oncolytic herpes simplex virus efficacy in patient-derived recurrent glioblastoma models

Shinichi Esaki et al.

INTERNATIONAL JOURNAL OF CANCER (2017)

添加到收藏夹

Article Multidisciplinary Sciences

In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target

Robert T. Manguso et al.

NATURE (2017)

添加到收藏夹

Article Oncology

Histone deacetylase inhibitor trichostatin A enhances the antitumor effect of the oncolytic adenovirus H101 on esophageal squamous cell carcinoma in vitro and in vivo

Junfen Ma et al.

ONCOLOGY LETTERS (2017)

添加到收藏夹

Article Multidisciplinary Sciences

Intratumoral modulation of the inducible co-stimulator ICOS by recombinant oncolytic virus promotes systemic anti-tumour immunity

Dmitriy Zamarin et al.

NATURE COMMUNICATIONS (2017)

添加到收藏夹

Article Multidisciplinary Sciences

Discovery of first-in-class reversible dual small molecule inhibitors against G9a and DNMTs in hematological malignancies

Edurne San Jose-Eneriz et al.

NATURE COMMUNICATIONS (2017)

添加到收藏夹

Article Multidisciplinary Sciences

Rational combination of oncolytic vaccinia virus and PD-L1 blockade works synergistically to enhance therapeutic efficacy

Zuqiang Liu et al.

NATURE COMMUNICATIONS (2017)

添加到收藏夹

Article Oncology

Aurora A kinase inhibition enhances oncolytic herpes virotherapy through cytotoxic synergy and innate cellular immune modulation

Mark A. Currier et al.

ONCOTARGET (2017)

添加到收藏夹

Review Oncology

Combination therapy in combating cancer

Reza Bayat Mokhtari et al.

ONCOTARGET (2017)

添加到收藏夹

Article Microbiology

HDAC6 controls innate immune and autophagy responses to TLR-mediated signalling by the intracellular bacteria Listeria monocytogenes

Olga Moreno-Gonzalo et al.

PLOS PATHOGENS (2017)

添加到收藏夹

Article Oncology

Reolysin and Histone Deacetylase Inhibition in the Treatment of Head and Neck Squamous Cell Carcinoma

Alena C. Jaime-Ramirez et al.

MOLECULAR THERAPY-ONCOLYTICS (2017)

添加到收藏夹

Article Oncology

TGF-β Inhibition Improves Oncolytic Herpes Viroimmunotherapy in Murine Models of Rhabdomyosarcoma

Brian Hutzen et al.

MOLECULAR THERAPY-ONCOLYTICS (2017)

添加到收藏夹

Review Oncology

Oncolytic Viruses in Cancer Treatment A Review

Sean E. Lawler et al.

JAMA ONCOLOGY (2017)

添加到收藏夹

Review Oncology

Oncolytic Viruses-Natural and Genetically Engineered Cancer Immunotherapies

Sachin R. Jhawar et al.

FRONTIERS IN ONCOLOGY (2017)

添加到收藏夹

Review Oncology

Oncolytic Viruses-Interaction of Virus and Tumor Cells in the Battle to Eliminate Cancer

Anwen Howells et al.

FRONTIERS IN ONCOLOGY (2017)

添加到收藏夹

Article Biochemistry & Molecular Biology

Combination Cancer Therapy Can Confer Benefit via Patient-to-Patient Variability without Drug Additivity or Synergy

Adam C. Palmer et al.

CELL (2017)

添加到收藏夹

Article Biochemistry & Molecular Biology

Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy

Antoni Ribas et al.

CELL (2017)

添加到收藏夹

Review Pharmacology & Pharmacy

Talimogene Laherparepvec: An Oncolytic Virus Therapy for Melanoma

Patricia A. Corrigan et al.

ANNALS OF PHARMACOTHERAPY (2017)

添加到收藏夹

Review Biochemistry & Molecular Biology

Taking a Stab at Cancer; Oncolytic Virus-Mediated Anti-Cancer Vaccination Strategies

Amelia Sadie Aitken et al.

BIOMEDICINES (2017)

添加到收藏夹

Article Oncology

PRC2 Epigenetically Silences Th1-Type Chemokines to Suppress Effector T-Cell Trafficking in Colon Cancer

Nisha Nagarsheth et al.

CANCER RESEARCH (2016)

添加到收藏夹

Article Oncology

Molecular Pathways: Mechanism of Action for Talimogene Laherparepvec, a New Oncolytic Virus Immunotherapy

Frederick J. Kohlhapp et al.

CLINICAL CANCER RESEARCH (2016)

添加到收藏夹

Review Pathology

The Roles of MDM2 and MDMX in Cancer

Orit Karni-Schmidt et al.

ANNUAL REVIEW OF PATHOLOGY: MECHANISMS OF DISEASE, VOL 11 (2016)

添加到收藏夹

Article Hematology

Gene expression-based discovery of atovaquone as a STAT3 inhibitor and anticancer agent

Michael Xiang et al.

BLOOD (2016)

添加到收藏夹

Article Oncology

Deubiquitination and Stabilization of PD-L1 by CSN5

Seung-Oe Lim et al.

CANCER CELL (2016)

添加到收藏夹

Article Biochemistry & Molecular Biology

A Small Molecule RAS-Mimetic Disrupts RAS Association with Effector Proteins to Block Signaling

Sai Krishna Athuluri-Divakar et al.

CELL (2016)

添加到收藏夹

Review Cell Biology

The Emerging Hallmarks of Cancer Metabolism

Natalya N. Pavlova et al.

CELL METABOLISM (2016)

添加到收藏夹

Article Oncology

Novel epi-virotherapeutic treatment of pancreatic cancer combining the oral histone deacetylase inhibitor resminostat with oncolytic measles vaccine virus

Tim Patrick Ellerhoff et al.

INTERNATIONAL JOURNAL OF ONCOLOGY (2016)

添加到收藏夹

Article Oncology

Histone Deacetylase Inhibitors Enhance the Therapeutic Potential of Reovirus in Multiple Myeloma

Andrew Stiff et al.

MOLECULAR CANCER THERAPEUTICS (2016)

添加到收藏夹

Article Multidisciplinary Sciences

Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells

Olivier De Henau et al.

NATURE (2016)

添加到收藏夹

Article Oncology

Macrophage PI3Kγ Drives Pancreatic Ductal Adenocarcinoma Progression

Megan M. Kaneda et al.

CANCER DISCOVERY (2016)

添加到收藏夹

Article Oncology

Modulation of chemokines in the tumor microenvironment enhances oncolytic virotherapy for colorectal cancer

Lily Francis et al.

ONCOTARGET (2016)

添加到收藏夹

Article Oncology

Oncolytic vaccinia virus combined with radiotherapy induces apoptotic cell death in sarcoma cells by down-regulating the inhibitors of apoptosis

Michelle J. Wilkinson et al.

ONCOTARGET (2016)

添加到收藏夹

Article Multidisciplinary Sciences

First-in-class small molecule potentiators of cancer virotherapy

Mark H. Dornan et al.

SCIENTIFIC REPORTS (2016)

添加到收藏夹

Article Cell Biology

BET Bromodomain Inhibition Promotes Anti-tumor Immunity by Suppressing PD-L1 Expression

Hengrui Zhu et al.

CELL REPORTS (2016)

添加到收藏夹

Article Oncology

Reprogramming antitumor immunity against chemoresistant ovarian cancer by a CXCR4 antagonist-armed viral oncotherapy

Marcin P. Komorowski et al.

MOLECULAR THERAPY-ONCOLYTICS (2016)

添加到收藏夹

Article Chemistry, Multidisciplinary

Blocking of the PD-1/PD-L1 Interaction by a D-Peptide Antagonist for Cancer Immunotherapy

Hao-Nan Chang et al.

ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2015)

添加到收藏夹

Review Oncology

Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies

J. Naidoo et al.

ANNALS OF ONCOLOGY (2015)

添加到收藏夹

Review Oncology

Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents

Lorenzo Galluzzi et al.

CANCER CELL (2015)

添加到收藏夹

Article Biotechnology & Applied Microbiology

Inhibition of the Aurora A kinase augments the anti-tumor efficacy of oncolytic measles virotherapy

I. D. Iankov et al.

CANCER GENE THERAPY (2015)

添加到收藏夹

Article Biochemistry & Molecular Biology

Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses

Katherine B. Chiappinelli et al.

CELL (2015)

添加到收藏夹

Review Endocrinology & Metabolism

Response and toxicity of small-molecule tyrosine kinase inhibitors in patients with thyroid carcinoma: a systematic review and meta-analysis

E. N. Klein Hesselink et al.

EUROPEAN JOURNAL OF ENDOCRINOLOGY (2015)

添加到收藏夹

Review Immunology

Metabolic Reprogramming of Immune Cells in Cancer Progression

Subhra K. Biswas

IMMUNITY (2015)

添加到收藏夹

Article Medicine, Research & Experimental

Histone deacetylase 6 inhibition enhances oncolytic viral replication in glioma

Hiroshi Nakashima et al.

JOURNAL OF CLINICAL INVESTIGATION (2015)

添加到收藏夹

Review Medicine, Research & Experimental

Targeting cancer with kinase inhibitors

Stefan Gross et al.

JOURNAL OF CLINICAL INVESTIGATION (2015)

添加到收藏夹

Article Oncology

Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma

Robert H. I. Andtbacka et al.

JOURNAL OF CLINICAL ONCOLOGY (2015)

添加到收藏夹

Article Biotechnology & Applied Microbiology

BRAF- and MEK-Targeted Small Molecule Inhibitors Exert Enhanced Antimelanoma Effects in Combination With Oncolytic Reovirus Through ER Stress

Victoria Roulstone et al.

MOLECULAR THERAPY (2015)

添加到收藏夹

Article Multidisciplinary Sciences

Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy

Dongjun Peng et al.

NATURE (2015)

添加到收藏夹

Article Multidisciplinary Sciences

The HDAC Inhibitors Scriptaid and LBH589 Combined with the Oncolytic Virus Delta24-RGD Exert Enhanced Anti-Tumor Efficacy in Patient-Derived Glioblastoma Cells

Lotte M. E. Berghauser Pont et al.

PLOS ONE (2015)

添加到收藏夹

Article Medicine, Research & Experimental

Signal Transduction in Cancer

Richard Sever et al.

COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2015)

添加到收藏夹

Editorial Material Oncology

Serum HMGB1 is a predictive and prognostic biomarker for oncolytic immunotherapy

Ilkka Liikanen et al.

ONCOIMMUNOLOGY (2015)

添加到收藏夹

Article Oncology

cu Combination of IFNα and poly-I:C reprograms bladder cancer microenvironment for enhanced CTL attraction

Ravikumar Muthuswamy et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2015)

添加到收藏夹

Review Oncology

Modulation of immune cell functions by the E3 ligase Cbl-b

Christina Lutz-Nicoladoni et al.

FRONTIERS IN ONCOLOGY (2015)

添加到收藏夹

Article Oncology

A Vaccinia Virus Armed with Interleukin-10 Is a Promising Therapeutic Agent for Treatment of Murine Pancreatic Cancer

Louisa S. Chard et al.

CLINICAL CANCER RESEARCH (2015)

添加到收藏夹

Review Immunology

Epigenetic control of myeloid cell differentiation, identity and function

Damiana Alvarez-Errico et al.

NATURE REVIEWS IMMUNOLOGY (2015)

添加到收藏夹

Article Oncology

Combination Treatment of Human Pancreatic Cancer Xenograft Models with the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Erlotinib and Oncolytic Herpes Simplex Virus HF10

Kazuo Yamamura et al.

ANNALS OF SURGICAL ONCOLOGY (2014)

添加到收藏夹

Article Oncology

Pharmacological modulation of autophagy enhances Newcastle disease virus-mediated oncolysis in drug-resistant lung cancer cells

Ke Jiang et al.

BMC CANCER (2014)

添加到收藏夹

Editorial Material Biotechnology & Applied Microbiology

Oncolytic viruses as platform for multimodal cancer therapeutics: a promising land

Z. S. Guo et al.

CANCER GENE THERAPY (2014)

添加到收藏夹

Article Oncology

Re-engineering Vesicular Stomatitis Virus to Abrogate Neurotoxicity, Circumvent Humoral Immunity, and Enhance Oncolytic Potency

Alexander Muik et al.

CANCER RESEARCH (2014)

添加到收藏夹

Article Oncology

Armed Oncolytic Virus Enhances Immune Functions of Chimeric Antigen Receptor-Modified T Cells in Solid Tumors

Nobuhiro Nishio et al.

CANCER RESEARCH (2014)

添加到收藏夹

Article Biochemistry & Molecular Biology

Vaccinia virus GLV-1h153 in combination with 131I shows increased efficiency in treating triple-negative breast cancer

Sepideh Gholami et al.

FASEB JOURNAL (2014)

添加到收藏夹

Review Medicine, Research & Experimental

New and emerging HDAC inhibitors for cancer treatment

Alison C. West et al.

JOURNAL OF CLINICAL INVESTIGATION (2014)

添加到收藏夹

Review Biotechnology & Applied Microbiology

Oncolytic Virotherapy and Immunogenic Cancer Cell Death: Sharpening the Sword for Improved Cancer Treatment Strategies

Samuel T. Workenhe et al.

MOLECULAR THERAPY (2014)

添加到收藏夹

Article Biotechnology & Applied Microbiology

T-cell Engager-armed Oncolytic Vaccinia Virus Significantly Enhances Antitumor Therapy

Feng Yu et al.

MOLECULAR THERAPY (2014)

添加到收藏夹

Article Oncology

PI3K inhibitor LY294002 inhibits activation of the Akt/mTOR pathway induced by an oncolytic adenovirus expressing TRAIL and sensitizes multiple myeloma cells to the oncolytic virus

Yin Tong et al.

ONCOLOGY REPORTS (2014)

添加到收藏夹

Article Oncology

AKT mediates actinomycin D-induced p53 expression

Chih-Shou Chen et al.

ONCOTARGET (2014)

添加到收藏夹

Article Oncology

Immunoglobulin-like transcript 2 (ILT2) is a biomarker of therapeutic response to oncolytic immunotherapy with vaccinia viruses

Andrew Zloza et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2014)

添加到收藏夹

Review Oncology

Activated Ras signaling pathways and reovirus oncolysis an update on the mechanism of preferential reovirus replication in cancer cells

Jun Gong et al.

FRONTIERS IN ONCOLOGY (2014)

添加到收藏夹

Review Oncology

Oncolytic immunotherapy: dying the right way is a key to eliciting potent antitumor immunity

Zong Sheng Guo et al.

FRONTIERS IN ONCOLOGY (2014)

添加到收藏夹

Article Hematology

The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo

Annkristin Heine et al.

BLOOD (2013)

添加到收藏夹

Article Biochemistry & Molecular Biology

Measles virus causes immunogenic cell death in human melanoma

O. G. Donnelly et al.

GENE THERAPY (2013)

添加到收藏夹

Article Oncology

The effectiveness of the oncolytic activity induced by Ad5/F35 adenoviral vector is dependent on the cumulative cellular conditions of survival and autophagy

So Y. Kim et al.

INTERNATIONAL JOURNAL OF ONCOLOGY (2013)

添加到收藏夹

Review Biochemistry & Molecular Biology

Oncolytic viruses as therapeutic cancer vaccines

David L. Bartlett et al.

MOLECULAR CANCER (2013)

添加到收藏夹

Article Biotechnology & Applied Microbiology

HDAC Inhibition Suppresses Primary Immune Responses, Enhances Secondary Immune Responses, and Abrogates Autoimmunity During Tumor Immunotherapy

Byram W. Bridle et al.

MOLECULAR THERAPY (2013)

添加到收藏夹

Article Biotechnology & Applied Microbiology

Suppression of Antiviral Innate Immunity by Sunitinib Enhances Oncolytic Virotherapy

Babal K. Jha et al.

MOLECULAR THERAPY (2013)

添加到收藏夹

Article Biochemistry & Molecular Biology

Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer

Jeong Heo et al.

NATURE MEDICINE (2013)

添加到收藏夹

Article Oncology

Oncolytic Vaccinia virus and radiotherapy in head and neck cancer

D. Mansfield et al.

ORAL ONCOLOGY (2013)

添加到收藏夹

Article Multidisciplinary Sciences

Targeting CXCL12/CXCR4 signaling with oncolytic virotherapy disrupts tumor vasculature and inhibits breast cancer metastases

Margaret Gil et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)

添加到收藏夹

Review Multidisciplinary Sciences

Epigenetic Reprogramming in Cancer

Mario L. Suva et al.

SCIENCE (2013)

添加到收藏夹

Article Genetics & Heredity

Exploiting tumor epigenetics to improve oncolytic virotherapy

Nicole E. Forbes et al.

Frontiers in Genetics (2013)

添加到收藏夹

Review Biochemistry & Molecular Biology

Cancer Epigenetics: From Mechanism to Therapy

Mark A. Dawson et al.

CELL (2012)

添加到收藏夹

Article Immunology

HPK1 as a novel target for cancer immunotherapy

Sansana Sawasdikosol et al.

IMMUNOLOGIC RESEARCH (2012)

添加到收藏夹

Review Biochemistry & Molecular Biology

The mTOR Signalling Pathway in Human Cancer

Helena Populo et al.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2012)

添加到收藏夹

Review Oncology

Discovery of small molecule cancer drugs: Successes, challenges and opportunities

Swen Hoelder et al.

MOLECULAR ONCOLOGY (2012)

添加到收藏夹

Article Biotechnology & Applied Microbiology

The Oncolytic Poxvirus JX-594 Selectively Replicates in and Destroys Cancer Cells Driven by Genetic Pathways Commonly Activated in Cancers

Kelley A. Parato et al.

MOLECULAR THERAPY (2012)

添加到收藏夹

Article Multidisciplinary Sciences

Orally bioavailable small-molecule inhibitor of transcription factor Stat3 regresses human breast and lung cancer xenografts

Xiaolei Zhang et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)

添加到收藏夹

Review Immunology

Evolutionary conflicts between viruses and restriction factors shape immunity

Nisha K. Duggal et al.

NATURE REVIEWS IMMUNOLOGY (2012)

添加到收藏夹

Article Oncology

A Novel Oncolytic Herpes Simplex Virus that Synergizes with Phosphoinositide 3-kinase/Akt Pathway Inhibitors to Target Glioblastoma Stem Cells

Ryuichi Kanai et al.

CLINICAL CANCER RESEARCH (2011)

添加到收藏夹

Article Oncology

Rapamycin enhances the activity of oncolytic herpes simplex virus against tumor cells that are resistant to virus replication

Xinping Fu et al.

INTERNATIONAL JOURNAL OF CANCER (2011)

添加到收藏夹

Article Biotechnology & Applied Microbiology

Targeting Tumor Vasculature With an Oncolytic Virus

Caroline J. Breitbach et al.

MOLECULAR THERAPY (2011)

添加到收藏夹

Article Biotechnology & Applied Microbiology

Sequential Therapy With JX-594, A Targeted Oncolytic Poxvirus, Followed by Sorafenib in Hepatocellular Carcinoma: Preclinical and Clinical Demonstration of Combination Efficacy

Jeong Heo et al.

MOLECULAR THERAPY (2011)

添加到收藏夹

Article Oncology

Local and Distant Immunity Induced by Intralesional Vaccination with an Oncolytic Herpes Virus Encoding GM-CSF in Patients with Stage IIIc and IV Melanoma

Howard L. Kaufman et al.

ANNALS OF SURGICAL ONCOLOGY (2010)

添加到收藏夹

Article Oncology

Myxoma Virus Virotherapy for Glioma in Immunocompetent Animal Models: Optimizing Administration Routes and Synergy with Rapamycin

XueQing Lun et al.

CANCER RESEARCH (2010)

添加到收藏夹

Article Biotechnology & Applied Microbiology

A High-throughput Pharmacoviral Approach Identifies Novel Oncolytic Virus Sensitizers

Jean-Simon Diallo et al.

MOLECULAR THERAPY (2010)

添加到收藏夹

Article Biotechnology & Applied Microbiology

Efficacy and Safety/Toxicity Study of Recombinant Vaccinia Virus JX-594 in Two Immunocompetent Animal Models of Glioma

XueQing Lun et al.

MOLECULAR THERAPY (2010)

添加到收藏夹

Review Biotechnology & Applied Microbiology

Intelligent Design: Combination Therapy With Oncolytic Viruses

Kathryn Ottolino-Perry et al.

MOLECULAR THERAPY (2010)

添加到收藏夹

Article Multidisciplinary Sciences

Vesicular stomatitis virus oncolysis is potentiated by impairing mTORC1-dependent type I IFN production

Tommy Alain et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)

添加到收藏夹

Article Cell Biology

Mutant p53 Gain-of-Function in Cancer

Moshe Oren et al.

COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2010)

添加到收藏夹

Review Pharmacology & Pharmacy

Therapeutic antibodies: successes, limitations and hopes for the future

Patrick Chames et al.

BRITISH JOURNAL OF PHARMACOLOGY (2009)

添加到收藏夹

Article Cell Biology

Specific activation of the p53 pathway by low dose actinomycin D A new route to p53 based cyclotherapy

Meng Ling Choong et al.

CELL CYCLE (2009)

添加到收藏夹

Article Oncology

Efficacy of Systemically Administered Oncolytic Vaccinia Virotherapy for Malignant Gliomas Is Enhanced by Combination Therapy with Rapamycin or Cyclophosphamide

Xue Qing Lun et al.

CLINICAL CANCER RESEARCH (2009)

添加到收藏夹

Review Genetics & Heredity

The many roles of histone deacetylases in development and physiology: implications for disease and therapy

Michael Haberland et al.

NATURE REVIEWS GENETICS (2009)

添加到收藏夹

Article Multidisciplinary Sciences

Inhibition of human tumor growth in mice by an oncolytic herpes simplex virus designed to target solely HER-2-positive cells

Laura Menotti et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)

添加到收藏夹

Review Oncology

Targeting the Stroma by T Cells to Limit Tumor Growth

Bin Zhang

CANCER RESEARCH (2008)

添加到收藏夹

Article Biochemistry & Molecular Biology

Inflammatory tumour cell killing by oncolytic reovirus for the treatment of melanoma

F. Errington et al.

GENE THERAPY (2008)

添加到收藏夹

Review Oncology

Oncolytic virotherapy as a personalized cancer vaccine

Qi-Xiang Li et al.

INTERNATIONAL JOURNAL OF CANCER (2008)

添加到收藏夹

Article Multidisciplinary Sciences

Chemical targeting of the innate antiviral response by histone deacetylase inhibitors renders refractory cancers sensitive to viral oncolysis

Thi Lien-Anh Nguyen et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)

添加到收藏夹

Article Oncology

Inhibition of JAK1, 2/STAT3 signaling induces apoptosis, cell cycle arrest, and reduces tumor cell invasion in colorectal cancer cells

Hua Xiong et al.

NEOPLASIA (2008)

添加到收藏夹

Article Oncology

Targeting human medulloblastoma: oncolytic virotherapy with myxoma virus is enhanced by rapamycin

Xue Qing Lun et al.

CANCER RESEARCH (2007)

添加到收藏夹

Review Biochemistry & Molecular Biology

Histone deacetylase inhibitors: molecular mechanisms of action

W. S. Xu et al.

ONCOGENE (2007)

添加到收藏夹

Article Immunology

Spontaneous tumor rejection by cbl-b-deficient CD8+ T cells

Stefanie Loeser et al.

JOURNAL OF EXPERIMENTAL MEDICINE (2007)

添加到收藏夹

Article Virology

Oncolytic virotherapy synergism with signaling inhibitors: Rapamycin increases myxoma virus tropism for human tumor cells

Marianne M. Stanford et al.

JOURNAL OF VIROLOGY (2007)

添加到收藏夹

Article Biotechnology & Applied Microbiology

Oncolytic HSV and erlotinib inhibit tumor growth and angiogenesis in a novel malignant peripheral nerve sheath tumor xenograft model

Yonatan Y. Mahller et al.

MOLECULAR THERAPY (2007)

添加到收藏夹

Review Biotechnology & Applied Microbiology

History of oncolytic viruses: Genesis to genetic engineering

Elizabeth Kelly et al.

MOLECULAR THERAPY (2007)

添加到收藏夹

Article Oncology

Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5

Li Liu et al.

CANCER RESEARCH (2006)

添加到收藏夹

Article Oncology

De novo induction of a cancer/testis antigen by 5-aza-2′-deoxycytidine augments adoptive immunotherapy in a murine tumor model

ZS Guo et al.

CANCER RESEARCH (2006)

添加到收藏夹

Review Biochemistry & Molecular Biology

Unshackling the links between reovirus oncolysis, Ras signaling, translational control and cancer

M Shmulevitz et al.

ONCOGENE (2005)

添加到收藏夹

Article Oncology

The enhanced tumor selectivity of an oncolytic vaccinia lacking the host range and antiapoptosis genes SPI-1 and SPI-2

ZS Guo et al.

CANCER RESEARCH (2005)

添加到收藏夹

Article Oncology

RAD001 (everolimus) improves the efficacy of replicating adenoviruses that target colon cancer

K Homicsko et al.

CANCER RESEARCH (2005)

添加到收藏夹

Article Oncology

α-type-1 polarized dendritic cells:: A novel immunization tool with optimized CTL-inducing activity

RB Mailliard et al.

CANCER RESEARCH (2004)

添加到收藏夹

Review Biochemistry & Molecular Biology

5-Azacytidine and 5-aza-2′-deoxycytidine as inhibitors of DNA methylation:: mechanistic studies and their implications for cancer therapy

JK Christman

ONCOGENE (2002)

添加到收藏夹

Article Oncology

EGFR and cancer prognosis

RI Nicholson et al.

EUROPEAN JOURNAL OF CANCER (2001)

添加到收藏夹

Article Biotechnology & Applied Microbiology

A novel approach to cancer therapy using an oncolytic herpes virus to package amplicons containing cytokine genes

JF Carew et al.

MOLECULAR THERAPY (2001)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.